Codon optimization of the human papillomavirus 11 (HPV 11) L1 gene leads to increased gene expression and formation of virus-like particles in mammalian epithelial cells  by Mossadegh, Nina et al.
www.elsevier.com/locate/yviro
Virology 326 (2004) 57–66Codon optimization of the human papillomavirus 11 (HPV 11)
L1 gene leads to increased gene expression and formation of
virus-like particles in mammalian epithelial cells
Nina Mossadegh,a,* Lutz Gissmann,a Martin Mu¨ller,a Hanswalter Zentgraf,a
Angel Alonso,a and Pascal Tomakidib
aResearch Program of Infection and Cancer, German Cancer Research Center, 69120 Heidelberg, Germany
bDepartment of Orthodontics and Dentofacial Orthopedics, Dental School, University of Heidelberg, Heidelberg, GermanyReceived 16 February 2004; returned to author for revision 24 March 2004; accepted 28 April 2004Abstract
The 505 amino acid L1 protein of the human papillomavirus type 11 (HPV 11) is the major capsid polypeptide that has been shown to
self-assemble into virus-like particles (VLPs) in vivo and in vitro. While L1 is essential for viral infection, expression studies in mammalian
cells have been hampered by different codon preference between the virus and its host. To optimize L1 gene expression in mammalian cells,
we converted wild-type HPV 11 L1 (11 L1wt) codons to those more common in human genes. The modified HPV 11 L1 gene (11 L1h)
generated protein levels that were at least 100-fold higher than those of wild-type HPV 11 L1, while no obvious differences were seen in the
level of mRNA. HPV 11 L1 protein was detected in mammalian epithelial and fibroblast cells, by immunoblotting and indirect
immunofluorescence (IIF) techniques. Unlike the situation in situ, IIF revealed the presence of L1 mainly at perinuclear sites. Virus-like
particles assembled intranuclearly only to a low extent, as indicated by transmission electron microscopy. DNAvaccination using the HPV 11
L1h gene yielded a drastic increase in L1-specific antibody production in mice as compared to immunization with the wild-type gene.
D 2004 Elsevier Inc. All rights reserved.Keywords: HPV 11; Major capsid protein L1; Codon optimization; Virus-like particles; Mammalian cellsIntroduction
Human papillomaviruses are small double-stranded DNA
viruses that are the causative agents of warts and have also
been associated with certain cancers in a variety of animal
hosts. High-risk human papillomaviruses, such as HPV type
16 and 18 play a critical role in the development of cervical
intraepithelial neoplasia and invasive cervical cancer (zur
Hausen, 1996). In contrast, the low-risk HPV types 6 and 11
are rarely associated with the progression of malignancies,
but they are responsible for benign genital warts, i.e., con-
dylomata acuminata, the most common sexually transmitted
viral disease (Gissmann et al., 1983; Koutsky et al., 1988).
Moreover, they are involved in recurrent respiratory papil-
lomatosis (RRP), a rare but serious condition, characterized0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: nina.mossadegh@dkfz.de (N. Mossadegh).by recurrent wart formation within the aerodigestive tract
(Gabbott et al., 1997; Gelder et al., 2003; Lele et al., 2002).
Considerable information is available concerning the patho-
genesis of high-risk HPV types, but little is known about the
virus life cycle, in particular of the low-risk HPV types.
Studies of the replication of papillomaviruses have been
hampered by the lack of a convenient cell culture system. The
tight regulation of late gene expression is linked to the
differentiation status of the infected host cell. In stratified
epithelia, the expression of HPV 11 and HPV 16 capsid genes
is confined to the differentiated cell layers, as demonstrated in
cultures of epithelial tissue (Flores et al., 1999; Stoler et al.,
1990). In vivo, this expression pattern is believed to contrib-
ute to the immune evasion of the virus (O’Brien and Saveria
Campo, 2002). Among the mechanisms proposed for the
regulation of papillomavirus late gene expression are (i) the
presence of inhibitory elements located on the late gene
mRNAs, as demonstrated for HPV 16 L1 (Collier et al.,
2002), and (ii) significant bias in codon usage between the
viral and the mammalian genes (Zhou et al., 1999). For
Table 1
Codon optimization of the HPV 11 L1 gene
Amino acid Codon Frequency (x)
HPV 11 L1wt HPV 11 L1h
Ala GCA 10 0
GCG 4 0
GCC 12 47.8
GCT 21.9 0
Arg AGA 10 43.8
AGG 8 0
CGA 6 0
CGG 4 0
CGC 8 0
CGT 8 0
Asn AAC 19.9 51.8
AAT 31.9 0
Asp GAC 15.9 57.8
GAT 41.8 0
Cys TGC 8 21.9
TGT 13.9 0
Gln CAA 23.9 0
CAG 21.9 45.8
Glu GAA 21.9 0
GAG 13.9 35.9
Gly GGA 15.9 0
GGG 12 0
GGC 10 75.7
GGT 37.8 0
His CAC 6 19.9
CAT 13.9 0
Ile ATA 8 0
ATC 2 23.9
ATT 13.9 0
Leu CTA 6 0
CTG 6 73.7
CTC 2 0
CTT 10 0
TTA 23.9 0
TTG 25.9 0
Lys AAA 37.8 2
AAG 27.9 63.7
Met ATG 23.9 23.9
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studies have shown that codon adaptation to human cells
results in an enhanced expression in these cells (Cid-Arregui
et al., 2003; Disbrow et al., 2003; Leder et al., 2001).
In the viral life cycle, the capsid proteins L1 and L2 form
the icosahedral capsid that packages the viral genomic DNA
within the nucleus (Zhou et al., 1995). Under in vitro
conditions, L1 alone or in conjunction with L2 is capable
to self-assemble into virus-like particles (VLPs) as demon-
strated by heterologous expression (Chen et al., 2001;
Hagensee et al., 1993; Kirnbauer et al., 1992; Neeper et
al., 1996; Rose et al., 1993). These VLPs resemble infec-
tious virions, thus becoming a promising tool for studies on
certain aspects of the early papillomaviruses life cycle such
as binding and uptake (Volpers et al., 1995). Unlike the
established systems, e.g., recombinant baculovirus (Le Cann
et al., 1994; Rose et al., 1993), the employment of a
mammalian expression system facilitates the production of
the L1 protein and the assembly of virus particles similar to
the in vivo conditions. In addition, expression in mamma-
lian cells allows studying the effects of late gene expression
on the host cell.
In this study, we aimed to generate an HPV 11 L1 gene
that, upon transfection into mammalian cells, produces
significant amounts of protein. To this end, we modified
the codon composition of the HPV 11 major capsid gene L1
by substituting all rarely used codons by those more
frequently found in human genes. Use of the newly engi-
neered gene (11 L1h) demonstrated that the substitution of
the codons led to a significant increase of protein expression
and resulted in the production of VLPs in mammalian cells.
Furthermore, the codon-optimized 11L1h gene induces a
strong immune response when compared to the nonmodified
sequence, as has been previously reported for major capsid
genes of other papillomavirus types, e.g., HPV 16 L1 and
HPV 6b L1 (Leder et al., 2001; Liu et al., 2001b).
Phe TTC 0 41.8
TTT 41.8 0
Pro CCA 17.9 0
CCG 4 0
CCC 17.9 71.7
CCT 31.9 0
Ser AGC 8 81.7
AGT 21.9 0
TCA 15.9 0
TCG 4 0
TCC 4 0
TCT 27.9 0
Thr ACA 33.9 0
ACG 4 0
ACC 17.9 67.7
ACT 12 0
Trp TGG 13.9 13.9
Tyr TAC 6 47.8
TAT 41.8 0Results
Construction of codon-modified HPV 11 L1 gene (11 L1h)
To increase the expression level of the HPV 11 major
capsid protein L1 in mammalian cells, we replaced all
codons by those more frequently used in mammalian genes
without modifying the protein sequence (Codon Usage
Database Kazusa, Table 1). The 11 L1h was generated from
synthetic oligonucleotides by fusion-PCR, and cloned into a
mammalian expression vector containing the human cyto-
megalovirus immediate–early promoter (pCMV). Inhibitory
sequences were described within AU-rich coding regions of
the HPV 16 L1 mRNA (Tan et al., 1995).
Val GTA 27.9 0
GTG 25.9 85.7
GTC 4 0
GTT 27.9 0
Notes to Table 1:
Comparison of codon usage frequency in the HPV 11 L1 wild-type and
HPV 11 L1 codon-modified gene.
Fig. 1. Expression of wild-type HPV 11 and codon-optimized HPV 11 L1
on the protein and mRNA level. (a) Increased L1 protein levels detected by
immunoblotting. Human 293T cells were transfected with 10 Ag of empty
vector (pcDNA3.1), wild-type L1 (pcDNA3.1-11 L1wt), or codon-
optimized L1 (pcDNA3.1-11 L1h) plasmid. Fifty micrograms of total
protein were separated by PAGE. L1 was detected by HPV 11 L1-specific
mAb. The level of 11 L1h compared with wild-type HPV 11 L1wt was
around 100-fold higher. A representative blot is shown. (b) Total RNAwas
isolated from transfected 293T and subjected to quantitative RT-PCR to
determine levels of L1 mRNA. The relative level of L1 RNA expression
was normalized to the level of neomycin RNA expression.
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Table 1) generated by the codon optimization of the HPV 11
L1 sequence would inactivate the putative negative regula-
tory elements within the wild-type L1 open reading frame
and, thus, further increases the expression level of the 11
L1h gene transfected into mammalian cells. The complete
codon-optimized 11 L1h sequence used in the current study
is deposited with GenBank under accession number
AY541029.
Expression of 11 L1wt and 11 L1h after transfection in
mammalian cells
To analyze the efficiency of the L1 constructs, the 11 L1h
and the 11 L1wt ORF placed under the control of the CMV
immediate early promoter were transiently transfected into
mammalian cells (Cos-1, 293T, and CHO-09). To control
for transfection efficiencies of the individual L1 expression
vectors, we cotransfected a plasmid expressing the EGFR-
gene. As shown in Fig. 1a for human 293T cells, the
expression of the L1 protein by 11 L1h was significantly
higher. Considering the level of EGFR (about 1.5 times
lower in the 11 L1h than in the 11 L1wt transfected cells;
Fig. 2a), we estimated the difference to be at least 100-fold
(Fig. 1a). This approximation seems to be underestimated,
because the 11 L1wt protein could not be detected at all.
We further investigated whether the higher protein ex-
pression by the 11 L1h gene was based on enhanced
translation of its mRNA. To this end, we performed real-
time quantitative RT-PCR to determine the level of 11 L1h
mRNA and the corresponding 11 L1wt transcript within the
transfected cells. The level of L1-specific mRNA was
normalized to the neomycin transcript derived from the
same vector, thus allowing a quantitative comparison of
the expression of the 11 L1h and 11 L1wt plasmids (Fig.
1b). In contrast to the protein expression results, the mRNA
level of 11 L1h mRNA was about twofold lower than 11
L1wt mRNA, indicating that the L1 gene expression is
posttranscriptionally regulated.
Localization of 11 L1h in mammalian cells
The increase in expression level of the 11 L1h gene
was corroborated by immunofluorescence techniques in
Cos-1 cells. Expression of the L1 protein was examined
48 h after transfection. While transient transfection of 11
L1wt did not lead to any detectable fluorescence above
the level of mock-transfected cells, the codon-optimized
gene yielded a strong signal.
The high expression of the 11 L1h gene allowed us to
analyze its subcellular localization in the transfected cells.
Both in Cos-1 and in CHO-09 cells, the L1 protein appeared
to be predominantly perinuclear with extension into the
cytoplasm when examined by confocal laser scanning mi-
croscopy. Bright field microscopy revealed an intact nucleus
(Fig. 2a) and fluorescence demonstrated the major proportionof 11 L1h being localized around the nucleus (Fig. 2b). This
was confirmed by superimposing the bright field and the
fluorescence (Fig. 2c), and visualized in more detail by set
stacks. The nucleus was mainly devoid of fluorescence, while
L1-specific fluorescence was clearly detectable in the cyto-
plasm and at perinuclear sites (Fig. 2d) demonstrating the
accumulation of 11 L1h in this region. This phenomenon was
also observed in CHO-09 cells, where the majority of L1-
transfected cells show predominantly L1 being localized
around the nuclei (Figs. 2e–g).
To further investigate the subcellular localization of the
HPV 11 L1 protein, we fractionated the cellular proteins by
N. Mossadegh et al. / Virology 326 (2004) 57–6660subcellular proteome extraction into a cytosolic, membra-
nous, nuclear, and cytoskeletal fraction. The respective use
of a calnexin (membrane protein) and a histone H1 (nuclear
protein) antibody confirmed the proper separation intoabove-mentioned distinct fractions. Interestingly, immuno-
blotting demonstrated the presence of HPV 11 L1 protein in
all fractions albeit at higher concentration in the nuclear and
cytoskeletal, than in the membranous or the cytosolic,
Fig. 3. Subcellular proteome extraction of 11 L1h-transfected cells 293T
cells were transfected with 10 Ag of the 11 L1h expression plasmid. The cell
lysate was separated into cytosolic, membranous, nuclear, and cytoskeletal
fractions. One percent of the protein content of each fraction was loaded
onto a SDS-PAGE, immunoblotted, and incubated with an anti-L1-specific
antibody. Calnexin and histone H1 were used as controls for proper
separation.
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L1 in the nuclear fraction does not necessarily indicate the
presence of this protein within the nucleus, but is more
likely a consequence of its binding to the nuclear membrane
copurified with the nuclear fraction (Fig. 3; see fluorescence
data in Fig. 2c). We hypothesize that the high abundance of
the L1 protein in the cytoskeletal fraction is due to an
association with microtubules as it has been shown for BPV-
1 L1 by coimmunoprecipitation experiments with L1 and
tubulin (Liu et al., 2001a, 2001b).
Assembly of virus-like particles (VLPs)
Next, we analyzed whether the increase in protein expres-
sion of 11 L1h leads to the formation of VLPs in mammalian
cells. We transfected 293T cells with the 11 L1h plasmid and
examined ultrathin sections by transmission electron micros-Fig. 2. Immunolocalization of HPV 11 L1 protein in Cos-1 and CHO-09 cells detec
empty vector (pcDNA3.1/mock), wild-type L1 (pcDNA3.1-11 L1wt), or codon-o
with the optimized Flag-tagged L1 (pCMV2-Flag-11L1h) plasmid. For IIF, cell
polyclonal anti-Flag antibody (CHO-09), followed by detection with a fluorochrom
absence of HPV 11 L1 expression in mock- and HPV 11 L1wt-transfected cells,
from the codon-optimized HPV 11 L1h gene. (a) bright field image of (b); (c) super
by set stack analysis (d). In CHO-09 cells, the L1 protein (green) was found to be m
propidium iodide (red, f ). (g) Superimposition of (e and f ).copy. As shown in Fig. 4, structures clearly resembling virus
capsids were found within the nucleus. This finding has been
corroborated by sucrose gradient centrifugation of extracts of
transfected cells. In lysates, positive signals for the HPV 11
L1 protein were detected (by Western blot analysis) in the
same fractions as VLPs produced in Sf9 insect cells (data not
shown). As comparison, we repeated transfection experi-
ments performed earlier with HPV 16 (Leder et al., 2001).
The amount of VLPs detected by EM was lower for HPV 11
as in case of HPV 16.
DNA immunization of mice with L1h-expressing plasmids
To analyze the ability of the codon-optimized 11 L1 gene
to form VLPs in vivo, we tested for the induction of an HPV
11 L1-specific humoral immune response in mice. Four
animal per group were injected twice intramuscularly at 2-
week intervals with either PBS, empty vector, or plasmid
DNA expressing 11 L1wt or 11 L1h, respectively. Sera
obtained 6 weeks after the first immunization were tested
by an L1-specific ELISA. Significant antibody titers were
elicited following injection of the 11 L1h plasmid, whereas
the response after immunization with the wild-type L1 gene
was only at background level (Fig. 5). While cross-reactivity
of HPV 11 L1 antibodies with the closely related HPV 6b L1
was detected (Fig. 5), no binding to HPV 16 L1was observed.Discussion
A major obstacle in cultivating HPV virions in vitro is
the tight linkage of replication to differentiating epithelia.
While expression of early genes can be observed throughout
a stratified epithelium, transcription of late genes occurs
only in suprabasal cells. One determinant of the low
expression level of papillomavirus (PV) genes in mamma-
lian cells seems to be their codon composition that differs
significantly from mammalian genes. In a study on the BPV-
1 major capsid L1 protein, addition of the matched amino-
acyl-tRNAs enhanced its expression in in vitro translation
experiments (Zhou et al., 1999).
Our objective was to design a synthetic HPV 11 L1 gene
that expresses the viral structural protein in a high amount in
mammalian cells. Altering the codon composition of the
wild-type HPV 11 L1 gene into a typical mammalian
sequence was expected to overcome the low expression
levels. In fact, Western blot analysis and indirect immuno-ted by indirect immunofluorescence (IIF). Cos-1 cells were transfected with
ptimized L1 (pcDNA3.1-11 L1h) plasmid. CHO-09 cells were transfected
s were stained with either CamVir L1-specific mab (Cos-1), or with the
e-coupled secondary antibody. Confocal laser scan microscopy revealed the
while a strong perinuclear fluorescence indicated L1 expression originating
imposition of (a and b). The perinuclear localization of L1 was corroborated
ainly localized at perinuclear sites (e). Cell nuclei were counterstained with
Fig. 5. HPV 11 L1-specific antibodies detected in the sera of mice
following DNA immunization. Mice were immunized either with plasmid
expressing HPV 11 L1h (black bars), HPV 11 L1wt (light gray bars)
expression plasmid or with PBS (dark gray bars). Six weeks after the first
immunization, mice were sacrificed and sera were diluted 1:50, and
analyzed for L1-specific antibodies by a GST-capture ELISA. Each bar
represents the mean absorbance (FSD) of all four mice per group. The sera
were tested against HPV 11 L1, -6b L1, -16 L1 GST-tag proteins or for
background reduction against GST-tag alone. Mice immunized with empty
vector showed antibody titers similar to antibody response in control mice
(PBS; data not shown).
Fig. 4. Assembly of virus-like particles (VLPs) in the nucleus of
mammalian 293T cells examined by transmission electron microscopy.
Cells grown on cover slips were fixed in glutaraldehyde and osmium
tetroxide and finally embedded in epoxide resin, preceding ethanol drying.
Ultrathin sections of HPV 11 L1h-transfected cells demonstrated the
presence of virus-like particles in the nucleus in a high-power (60.000 )
magnification. cp: cytoplasm; nm: nuclear membrane.
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the HPV 11 L1 gene leads at least to a 100-fold increase in
protein expression when compared to the HPV 11 L1wt
gene.
Since the amino acid sequence of both the codon-
optimized and the wild-type gene is identical, the higher
levels are likely not the consequence of altered protein
stability. This conclusion is supported by earlier findings
on the HPV 16 E7 protein whose half-life was reported to be
identical independent on composition (wt or modified) of
the coding gene (Cid-Arregui et al., 2003). Analysis of the
newly synthesized 11 L1h transcription using quantitative
real-time PCR revealed that the level of mRNA was even
lower when compared to 11 L1wt mRNA. Thus, the reasons
for the difference in the amount of synthesized protein are so
far unknown, but analysis of the Kozak sequence in the
optimized and wt mRNA suggests that the changes caused
by optimization are not responsible for the enhanced L1
translation (Wingender et al., 2002).
We took advantage of the high level of the L1 gene
expression to study its localization in mammalian cells in
culture. Because DNA replication takes place inside the
nucleus, nuclear import of the viral capsid proteins L1 and
L2 is required for packaging of the viral DNA. Our data
obtained by IIF laser confocal microscopy revealed a strong
L1-specific perinuclear staining within the transfected cells,
while only small amount of L1 protein was detected inside
the nucleus. This is in contrast to previous reports where
HPV 1 L1 or 16 L1 protein was mainly found in the nucleus(Ghim et al., 1992; Leder et al., 2001). It is conceivable that
the high abundance of the L1 protein expressed from the
modified gene led to the formation of protein aggregates in
the cytoplasm that are excluded from the passage through
the nuclear pores. To further clarify the phenomenon of
nuclear import, additional experiments in different mamma-
lian cell types are in progress.
Previous reports on the heterologous expression of the
L1 gene of different papillomaviruses including HPV 6, 11,
and 16 in E. coli, yeast, or insect cells have demonstrated
that the L1 protein has the ability to self-assemble into viral
particles, with similar structural and immunological features
to native empty virions (Chen et al., 2001; Hagensee et al.,
1993; Kirnbauer et al., 1992; Neeper et al., 1996; Rose et
al., 1993). In this study, we clearly proved the presence of
VLPs in mammalian cells, albeit at a lower extent when
compared to cells transfected with the codon-optimized
HPV 16 L1 gene (Leder et al., 2001). This is in accordance
with our IIF results displaying a limited import of the L1
protein into the nucleus. Nevertheless, the modified 11 L1
gene led to the expression of L1 protein, properly folded
into VLP-like structures in mammalian cell and thus repre-
sents an experimental system for future studies on the effect
of papillomavirus late gene expression in host cells. Our
data on higher protein expression level using the 11 L1h
gene and on the formation of VLPs were confirmed by
immunization experiments yielding a high titer of antisera
specific for HPV 11 VLPs (Fig. 5).
Another aspect regarding the generation of the 11 L1h
gene is the application as DNA vaccine. The psycholog-
ical impact for the patient of suffering from genital warts
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propensity for malignant transformation. Treatment of this
common sexually transmitted disease consists primarily of
ablation or removal of infected tissues and often results
in painful, extensive, slow-healing ulcerations and fre-
quent early relapse, although antiviral and immunomod-
ulatory drugs have also been shown to have some
therapeutic benefit (Gross, 2001; Maw and von Krogh,
2000; Moore et al., 2001). Further, for HPV-11-induced
recurrent respiratory papillomatosis, none of the existing
medical treatment has been universally successful as well
so far, so that surgical removal is inevitable (Williams et
al., 2002).
Thus, the development of HPV vaccines to prevent the
effects of both high-risk and low-risk HPV infection is
doubtlessly of great value. Besides HPV protein-based
vaccines as VLPs, DNA vaccines, which are simple to
produce, less expensive, and heat-stable, are under inves-
tigation. They encode for antigenic molecules that are
produced and presented in a natural way by in vivo
transfected cells. In contrast to HPV VLP-based vaccines,
they provide the possibility for the construction of
multivalent genes (i.e. HPV-6 L1, HPV 11 L1, and
HPV 16 L1), thus contributing to a broader range of
immunogenicity.
In our study, we demonstrated that vaccination with the
11 L1h gene induced an HPV 11 L1-specific humoral
immune response, whereas no significant amount of L1-
specific antibodies was obtained in the wild-type L1-immu-
nized mice. Similar results were previously obtained with
other codon-optimized papillomavirus major capsid genes
such as HPV 16 L1 and HPV 6b L1 (Leder et al., 2001; Liu
et al., 2001b). The specificity of the HPV 11 L1 antibodies
derived after immunization was tested by exposing the
antibodies against the HPV 6b and 16 L1 proteins, respec-
tively. While no reaction was seen in case of HPV 16,
binding of the HPV 11 L1 antibodies to HPV 6b L1 was
observed indicating a cross reactivity of the sera related to
the high degree of homology in the amino acid sequence of
the two L1 capsid proteins.
In summary, our results demonstrate that HPV 11 L1
gene expression might be subjected to tight regulation in
mammalian cells because of existent differences in codon
usage. This phenomenon might be a factor of HPV
survival strategy, because low amounts of viral proteins
could prevent the induction of the immune system, thus
facilitating persistent infection. The codon-optimized ma-
jor capsid protein L1 revealed strong increase in expres-
sion level in mammalian cells, while preserving the
capability of self-assembly into virus-like particles. To
gain a sufficient amount of particles for the use in
infection studies, further experiments that focus on the
optimization of the nuclear import of the 11 L1h protein
have to be performed in the future. Nevertheless, the high
protein amount expressed from the 11 L1h gene facilitates
the analysis of late events following HPV 11 infection inmammalian cells. To this end, our further research will
focus on the influence of the major capsid protein on the
cellular proteome by using 2D Page and Maldi-TOF mass
spectrometry.
Finally, we received promising results in mice immu-
nization experiments by achieving the production of HPV
11 L1-specific antibodies after DNA vaccination using the
codon-optimized L1 gene. This induction of significant
titers of antibodies may render the 11 L1h gene a useful
tool to generate vaccines for the prevention of benign
lesions.Materials and methods
Construction of a codon-modified HPV 11 L1 gene
For engineering of the synthetic, codon-modified HPV
11 L1 gene (11 L1h), 13 pairs of oligonucleotides were
synthesized and used in a template-free PCR. The coding
region was designed to contain the most frequently used
codons found in highly expressed genes in Homo sapiens
according to the codon usage table taken from GenBank
Database. The sense strand primers started with an added
EcoRI restriction site 5V to the initiation codon and
continued as contiguous oligonucleotides, terminating 20
bases from the end of the gene. The antisense strand
oligonucleotides started with an appended HindIII site 3V
of the L1 stop codon and continued as contiguous
oligonucleotides, ending 20 bases from the start of the
gene. In this manner, the overlapping oligonucleotides
acted as primers for the opposite strand. The synthetic
gene was generated by two consecutive PCR-reactions.
Due to the large size of the L1 sequence, the complete
gene was built up of three overlapping fragments, span-
ning the entire L1 gene and each generated using the
following PCR method. To allow high-fidelity amplifica-
tion, Pwo DNA polymerase (Roche, Mannheim, Ger-
many) was used. The assembly of the oligonucleotides
was achieved in a first PCR reaction, by combining equal
amounts of each oligonucleotide. In a second PCR,
an aliquot of the gene assembly reaction mixture was
mixed with the first sense strand and the first antistrand
primer of the respective fragment, displaying its start and
end, and, thus, allowing the amplification of each frag-
ment. The fragments were isolated from the PCR mix-
tures by agarose gel electrophoresis, purified with QiaexII
(Qiagen, Hilden, Germany). The single fragments were
first cloned into the pCR2.1 vector by using the TOPO
TA cloning kit (Invitrogen, Karlsruhe, Germany), se-
quenced, and mutations were removed by site-directed
mutagenesis. Finally, the three fragments were digested
with appropriate restriction endonucleases, and cloned
successively into the multiple cloning site of pBSK+,
resulting in the complete optimized 11 L1h gene. The
sequence of the complete clone was confirmed by the
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11 L1h gene was cloned into the mammalian expression
vectors pcDNA3.1 and pFlag-CMV2.
Cell lines and transfections
Cos-1 (African green monkey kidney cells, ATCC #
CRL-1650 ), 293T (Human embryonic kidney cells, ATCC
# CRL-11268), and CHO-09 (Chinese hamster ovary cells,
kindly provided by J.A. Maassen from the University of
Leiden) cells were grown in Dulbecco’s modified Eagle’s
Medium supplemented with 10% heat-inactivated fetal calf
serum and 1% penicillin–streptomycin. All cell lines were
cultivated in a humidified atmosphere with 5% CO2 at 37
jC. Transfection was carried out depending on the cell type
at 40–90% confluence by using Lipofectamine 2000 (Invi-
trogen) according to the manufacturer’s instructions or by
the calcium phosphate precipitation method.
DNA immunization
Six-week-old female Balb/c mice were used for DNA
immunization experiments with Qiagen purified plasmid
dissolved in phosphate-buffered saline (PBS) to a final
concentration of 1 mg/ml. For each construct, the immu-
nization was carried out twice within 4 weeks by intra-
muscularly injecting (i.m.) 50 Ag of plasmid into each of
the anterior tibialis muscle. Five days before each immu-
nization, mice were treated with Cardiotoxin (0,0625 mg/
ml, Latoxan, New York) to induce a local inflammation.
During immunization, mice were anesthetized with Meto-
fane (Janssen-Cilag, Neuss, Germany). After another 2
weeks, mice were sacrificed by cervical dislocation, blood
was collected by cardiac puncture, and sera were tested for
11 L1 antibodies in a HPV 11 L1-specific GST-capture
ELISA.
ELISA
For the detection of HPV 11 L1-specific antibodies in the
sera of the immunized mice, a GST-capture ELISA was
performed according to the method of Sehr et al. (2001). For
this purpose, microtiter plates were coated with 200 ng/well
of glutathione casein in 50 mM carbonate buffer, pH 9.6, at
4 jC overnight. The next day, the coating buffer was
replaced by 180 Al/well blocking buffer (0.2% w/v casein
in PBS, 0.05% Tween 20) and incubated 1 h at 37 jC. After
removing the blocking buffer, the cleared lysates from E.
coli strain BL21 expressing GST-HPV 11 L1 proteins
diluted in blocking buffer to a concentration of 0.25 Ag/
Al total lysate protein were added and incubated for 1 h at
room temperature. Then, mice sera were diluted 1:50 in
blocking buffer containing 0.25 Ag/Al total lysate protein
from the parental E. coli-strain BL21 and incubated for 1 h at
4 jC to block reaction of the sera with contaminating E. coli
proteins. Coated ELISA plates were then incubated for 1 hwith 100 Al/well of diluted and preincubated serum. Bound
HPV 11 L1-specific antibodies were detected by goat anti-
mouse IgG/M polyclonal antibody conjugated to HRP (1:
10000 dilution in blocking buffer, incubation for 1 h at room
temperature; Dianova, Hamburg, Germany). Then, plates
were washed and the color reaction using tetramethylbenzi-
dine (Sigma, Munich, Germany) (10 mg/ml in 0.1 M
NaAcetate, pH 6.0, 0.003% H2O2, 100 Al/well) as substrate
was started. After 8 min, the enzyme reaction was stopped
by adding 50 Al of 1 M sulfuric acid per well and the
absorbance at 450 nm was measured in a automated ELISA
plate reader. As a control, sera were tested for binding to
GST-HPV-6b L1 and GST HPV 16 L1 proteins produced in
E. coli. Readings obtained with GST tag protein were
subtracted as background.
Western blot analysis
Cells growing on 10-cm-diameter dish were transfected
with 10 Ag of the various plasmids, and allowed to express
the protein for 48 h. Then, cells were washed twice with ice-
cold PBS and lysed in 1% sodium dodecyl sulfate (SDS)
loading buffer by heating to 95 jC for 5 min.
Protein concentrations were determined using the Bio-
Rad detergent compatible kit (Bio-Rad, Munich, Germany)
as suggested by the manufacturer. In all cases, 50 Ag of
protein were separated on 12.5% polyacrylamide gels by
SDS polyacrylamide gel electrophoresis (PAGE), and blot-
ted onto nitrocellulose membranes. The filters were blocked
overnight at 4 jC in PBS–0.1% Tween 20 containing 5%
skim milk powder (blocking solution) and were then incu-
bated for 1 h at room temperature with the monoclonal
antibody CamVir-1 (BD Pharmingen, San Diego, USA;
1:2000 in blocking solution), the polyclonal rabbit anti-Flag
antibody (Sigma-Aldrich; diluted 1:1000 in blocking solu-
tion), the polyclonal goat anti-Calnexin (Santa Cruz, Hei-
delberg, Germany; diluted 1:100 in blocking solution), or
with the Hybridoma anti-histone H1 antibody (hybridoma
cells were kindly provided by S. Khochbin from the
University Joseph Fourier, Inserm, Institute Albert-Bonniot,
Grenoble), respectively. The membranes were washed 3
times in PBS–0.1% Tween 20 for 5 min and then incubated
with a peroxidase-coupled goat anti-mouse or goat anti-
rabbit antibody diluted 1:10,000 in blocking solution for 1
h at room temperature. After being washed, 11 L1 protein
was detected using an enhanced chemiluminescence detec-
tion kit (Amersham, Braunschweig, Germany).
Indirect immunofluorescence (IIF)
Cells growing on glass cover slips were fixed 48 h after
transfection via incubation in  20 jC methanol (5 min)
and acetone (20 s) at 4 jC and then air dried and rehydrated
in PBS for 5 min. The cells were incubated with the
monoclonal antibody CamVir-1 (BD Pharmingen) diluted
1:20 or the polyclonal anti-Flag antibody (Sigma-Aldrich)
N. Mossadegh et al. / Virology 326 (2004) 57–66 65diluted 1:160 in PBS containing 0.3% bovine serum albu-
min for 1 h at room temperature. The cells were then
washed 3 times in PBS and incubated with fluorochrome-
conjugated anti-mouse or anti-rabbit secondary antibody
(Mo Bi Tec Go¨ttingen, Germany) diluted 1:100 in PBS
containing 1% skim milk powder for 1 h at room temper-
ature. After being washed 3 times in PBS, the slides were
embedded in Fluoprep (bioMe´rieux, Nu¨rtingen, Germany)
and analyzed with a confocal laser scanning microscope,
Leica TCS SP (Leica, Bensheim, Germany). In case of cell
nuclei counterstain, propidium iodide (0.5 mg/ml) was
added to the secondary antibody.
Electron microscopy
To visualize VLPs after transient transfection, cells were
grown on cover slips, washed with PBS containing 1 mM
MgCl2, and fixed for 30 min with 2.5% glutaraldehyde
(Serva, Heidelberg, Germany) in cacodyle-buffer followed
by a second fixation step with osmium tetroxide (Poly-
science, Niles, USA). After dehydration with increasing
concentrations of ethanol, cells were embedded in epoxide
resin. Ultrathin sections (50 nm) of the cells were stained
with 1% uranyl acetate and lead citrate. The sections were
examined with a Zeiss EM 10A microscope (Zeiss, Ober-
kochen, Germany).
Subcellular proteome extraction
Cells growing on a six-well-plate were transfected with 2
Ag of the codon-optimized 11 L1-gene. Forty-eight hours
after transient transfection, cellular proteins were separated
into a cytosolic, a membranous, a nuclear, and a cytoskeletal
fraction according to the manufacturer’s protocol of the
subcellular proteome extraction kit (Calbiochem, Darmstadt,
Germany). Protein concentrations of the above-mentioned
fractions were determined by the DC protein Assay (Bio-
Rad). One percent of the protein amount of each fraction was
analyzed by Western blotting as described above.
Quantitative RT-PCR of L1 mRNA
Cells were transiently transfected with either pcDNA3.1,
11 L1wt, or 11 L1h. Forty-eight hours later, total RNA was
isolated using the RNeasy Mini Kit (Qiagen). The reverse
transcription reaction was carried out using the iScript
cDNA synthesis kit (Bio-Rad) containing both oligo (dT)
and random hexamer primers. The PCR oligonucleotides
for the neomycin gene were S-5V-TGA ATG AAC TGC
AGG ACG AG-3V and AS-5V-ATA CTT TCT CGG CAG
GAG CA-3V. For the 11 L1wt gene, the primer oligonucleo-
tides were S-5V-GCCATGTGGAGGAGTTTGAT-3Vand AS-
5V-AGGTGTGGGTTTCTGACAGG-3V. For the 11 L1h
gene, the PCR oligonucleotides were S-5V-AGGT-
GATGGCCTACATCCAC-3V and AS-5V-CTGGTTCTG-
CCTCTGTAGCC-3V.Real-time PCR was performed using the iQ SYBR Green
Supermix (Bio-Rad) on an iCycler real-time PCR machine
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